Johnson & Johnson's COVID vaccine moves into final stage of trials
Pharmaceutical giant Johnson & Johnson announced Thursday that it has fully enrolled participants for the first late-stage trial of its COVID-19 single-dose vaccine candidate, CNN reports.
The company's Jansen unit is leading the study, which involves 45,000 participants and has been named 'Ensemble.'
According to CNN, the company believes that with the high rate of disease transmission among the general population in the United States, this number of volunteers should be enough to quickly get the data the company needs to determine if the vaccine works and to determine if it is safe.
If the study's data reveals that the drug is a viable option for Americans, the company anticipates submitting its request for emergency use authorization to the U.S. Food and Drug Administration (FDA) in February.
Desktop NewsClick to open Continuous News in a sidebar that updates in real-time.
Baton Rouge rapper NBA YoungBoy pleads not guilty to federal weapons charges
Officials with EBR Schools face pushback from community over 'Smart Start' plan
Thursday's 2 Your Health Report
Roofers slammed after hail storms damage properties in Ascension
Parish offers 'no comment' to eroding drainage ditch issue in Prairieville
'We have a plan': Coach O quiet on how Title IX scandal...
Southeastern regains sole possession of first place in Southland standings with win...
Max Johnson in the mix for LSU starting quarterback job
Coach O admits to mistakes, takes steps to correct them in the...
Saints QB Jameis Winston gets emotional discussing Drew Brees